Viatris-collaborated trial registered comparing Yupelri/Perforomist combo to standard COPD therapy
A University of Tennessee-led Phase 4 study with Viatris Inc. as collaborator will test nebulized long-acting bronchodilators against short-acting standard care in ED patients with acute COPD exacerbation.
One new trial entry appeared this week involving a Viatris-collaborated study in COPD.
- A Phase 4 trial titled "Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)" was first posted on 2026-07-23 with status not yet recruiting. The study is sponsored by the University of Tennessee Graduate School of Medicine, with Viatris Inc. listed as a collaborator1. The trial plans to enroll 280 participants1 and will compare Revefenacin (YUPELRI) and Formoterol (Perforomist)1 against Albuterol and Ipratropium (Atrovent/Ventolin)1, with the primary outcome being the difference in Modified Borg Dyspnea Scale scores between groups from enrollment through Day 71. Estimated start is 2026-09-01, with primary completion estimated for 2028-09-01.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.